These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 35487327)

  • 21. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia.
    Huang T; Bedford HM; Rashid S; Rasasakaram E; Priston M; Mak-Tam E; Gibbons C; Meschino WS; Cuckle H; Mei-Dan E
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):190. PubMed ID: 35260099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
    McLaughlin K; Hobson SR; Chandran AR; Agrawal S; Windrim RC; Parks WT; Bowman AW; Sovio U; Smith GC; Kingdom JC
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1145-S1156.e1. PubMed ID: 34461078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy outcomes in women with chronic kidney disease and chronic hypertension: a National cohort study.
    Al Khalaf SY; O'Reilly ÉJ; McCarthy FP; Kublickas M; Kublickiene K; Khashan AS
    Am J Obstet Gynecol; 2021 Sep; 225(3):298.e1-298.e20. PubMed ID: 33823152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers.
    Gaccioli F; Aye ILMH; Sovio U; Charnock-Jones DS; Smith GCS
    Am J Obstet Gynecol; 2018 Feb; 218(2S):S725-S737. PubMed ID: 29275822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
    Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
    Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.
    Chaiworapongsa T; Romero R; Gotsch F; Suksai M; Gallo DM; Jung E; Krieger A; Chaemsaithong P; Erez O; Tarca AL
    Am J Obstet Gynecol; 2023 May; 228(5):569.e1-569.e24. PubMed ID: 36336082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of biochemical tests of placental function for improving pregnancy outcome.
    Heazell AE; Whitworth M; Duley L; Thornton JG
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011202. PubMed ID: 26602956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of stillbirth and adverse pregnancy outcomes in a third pregnancy when an earlier pregnancy has ended in stillbirth.
    Al Khalaf S; Kublickiene K; Kublickas M; Khashan AS; Heazell AEP
    Acta Obstet Gynecol Scand; 2024 Jan; 103(1):111-120. PubMed ID: 37891707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
    Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
    Espinoza J; Romero R; Nien JK; Gomez R; Kusanovic JP; Gonçalves LF; Medina L; Edwin S; Hassan S; Carstens M; Gonzalez R
    Am J Obstet Gynecol; 2007 Apr; 196(4):326.e1-13. PubMed ID: 17403407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prognostic model to guide decision-making on timing of delivery in late preterm pre-eclampsia: the PEACOCK prospective cohort study.
    Duhig K; Seed PT; Placzek A; Sparkes J; Gill C; Brockbank A; Shennan A; Thangaratinam S; Chappell LC
    Health Technol Assess; 2021 May; 25(30):1-32. PubMed ID: 34024312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic Classification of Preterm Birth Among Nulliparous Women: A Population-Based Cohort Study.
    Maghsoudlou S; Yu ZM; Beyene J; McDonald SD
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1423-1432.e9. PubMed ID: 31053564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.
    Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA
    Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
    Ciobanou A; Jabak S; De Castro H; Frei L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Jul; 54(1):79-86. PubMed ID: 31100188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of physical activity on placental analytes in nulliparous persons.
    Whorton AE; Pan AY; Palatnik A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jan; 292():158-162. PubMed ID: 38016416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.